Increasing competition in molecular diagnostics
New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.
high · management_commentary3B Blackbio DX Ltd — Q3 FY26
3B Blackbio reported 9-month revenue of ₹99.06 crore, up 11.8% YoY (or ~20% excluding seasonal flu spikes).
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
HAT contract sunset risk
The WHO HAT contract (~$1.5M/year) will end in ~2 years; replacement revenue from US FDA is uncertain.
medium · analyst_questionSlow NGS adoption and low margins
NGS segment has low margins and slow traction; management views it as a technology hedge rather than a growth driver.
low · management_commentaryCredit period extension impacting cash flow
Industry credit periods have extended to 3-5 months, matching competitors, which could pressure working capital.
medium · analyst_question